Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
arcticnovartis

  • Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer 
  • The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Kα mutations in breast cancer while sparing wild-type PI3Kα, thus reducing unwanted side effects and improving tolerability
/by

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
arcticnovartis

  • Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer 
  • The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Kα mutations in breast cancer while sparing wild-type PI3Kα, thus reducing unwanted side effects and improving tolerability
/by

Building the Future: Novartis Innovation Lab – AI, Game Studio, XR & Emerging Tech

Building the Future: Novartis Innovation Lab – AI, Game Studio, XR & Emerging Tech
halesmi2

/by

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
arcticnovartis

  • Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 

  • HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 

  • Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1 
/by

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
arcticnovartis

  • Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 

     

  • HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 

     

  • Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1 
/by

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
arcticnovartis

  • Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 

     

  • HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 

     

  • Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1 
/by

Bringing proteins together to take cancer apart

Bringing proteins together to take cancer apart
halesmi2

/by

Bringing proteins together to take cancer apart

Bringing proteins together to take cancer apart
halesmi2

/by

Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut

Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut
arcticnovartis

  • Die Aktionärinnen und Aktionäre genehmigten die 29. Dividendenerhöhung in Folge. Für 2025 wird die Dividende auf CHF 3.70 (+5,7%) je Aktie erhöht, was einer Rendite von 3,0% entspricht¹

  • Die Aktionärinnen und Aktionäre bestätigten Giovanni Caforio als Vorsitzenden des Verwaltungsrats sowie alle weiteren Mitglieder des Verwaltungsrats die zur Wiederwahl standen. Charles Swanton wurde zum neuen Mitglied des Verwaltungsrats gewählt.
/by

Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut

Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut
arcticnovartis

  • Die Aktionärinnen und Aktionäre genehmigten die 29. Dividendenerhöhung in Folge. Für 2025 wird die Dividende auf CHF 3.70 (+5,7%) je Aktie erhöht, was einer Rendite von 3,0% entspricht¹

  • Die Aktionärinnen und Aktionäre bestätigten Giovanni Caforio als Vorsitzenden des Verwaltungsrats sowie alle weiteren Mitglieder des Verwaltungsrats die zur Wiederwahl standen. Charles Swanton wurde zum neuen Mitglied des Verwaltungsrats gewählt.
/by